What Is Glioblastoma—and Why Is It So Hard to Treat?
Glioblastoma is the most aggressive brain cancer, with a median survival of just 15 months. Here's how it grows, why the blood-brain barrier blocks treatment, and what new research offers hope.
The Deadliest Brain Tumor
Glioblastoma, formerly known as glioblastoma multiforme (GBM), is the most common and most aggressive cancerous brain tumor in adults. It arises from star-shaped glial cells called astrocytes, which normally support and protect neurons. When these cells turn malignant, they form a grade IV tumor — the highest and most dangerous classification in the World Health Organization's brain tumor grading system.
Each year, roughly 12,000 people in the United States alone receive a glioblastoma diagnosis. The median survival is approximately 15 months with standard treatment, and the five-year survival rate hovers around just 5%. Among the prominent people who have battled the disease are U.S. Senator John McCain and Beau Biden, son of President Joe Biden.
How Glioblastoma Grows
What makes GBM so lethal starts at the cellular level. The tumor is extraordinarily heterogeneous — a single mass can contain multiple genetically distinct populations of cancer cells, each responding differently to treatment. This built-in diversity means a therapy that kills one subpopulation may leave another untouched.
GBM cells also grow rapidly and recruit dense networks of blood vessels to feed themselves through a process called angiogenesis. Most critically, the tumor sends finger-like projections deep into surrounding healthy brain tissue. These invasive tendrils make complete surgical removal virtually impossible — no matter how precise the surgeon, microscopic cancer cells almost always remain behind, seeding recurrence.
The Blood-Brain Barrier Problem
The brain is shielded by the blood-brain barrier (BBB), a tightly sealed network of endothelial cells that blocks roughly 98% of small-molecule drugs and nearly all large biological therapies — including monoclonal antibodies — from entering brain tissue. In healthy people, this is a vital defense. For glioblastoma patients, it is a therapeutic nightmare.
While the tumor does partially disrupt the barrier at its core, the disruption is uneven and insufficient. Worse, the infiltrating cancer cells at the tumor's edges sit behind an intact BBB, shielded from chemotherapy. These surviving cells are what drive the near-inevitable fatal recurrence, according to research published in Nature Reviews Cancer.
A Microenvironment That Fights Back
GBM doesn't just grow — it actively reprograms its surroundings. The tumor microenvironment is a complex ecosystem of immune cells, astrocytes, and other brain-resident cells that glioblastoma hijacks to promote its own survival. Cancer cells secrete signals that suppress the immune response, essentially telling the body's defenses to stand down.
Recent research from McMaster University and SickKids revealed that even oligodendrocytes — cells normally responsible for insulating nerve fibers — can switch roles and actively fuel tumor growth. When researchers blocked this communication pathway in lab models, tumor growth slowed dramatically.
Standard Treatment and Its Limits
The current standard of care, largely unchanged for two decades, follows a three-step protocol known as the Stupp regimen: maximum safe surgical removal, followed by radiation therapy combined with the chemotherapy drug temozolomide. While this approach extends survival, it is not curative.
A newer addition, Tumor Treating Fields (TTFields), delivers low-intensity electric fields to the tumor site through a wearable device. A USC study found that combining TTFields with immunotherapy and chemotherapy was associated with a 70% increase in overall survival, and a large Phase 3 trial is now underway across 28 sites in the U.S., Europe, and Israel.
Where Research Is Heading
Scientists are pursuing multiple fronts. Immunotherapy — including checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines — aims to retrain the immune system to recognize and attack GBM cells. The dendritic cell vaccine DCVax-L has shown promising Phase III results, extending median survival to over 19 months for newly diagnosed patients.
Gene therapy approaches are also emerging. Researchers at the University of Edinburgh have developed a viral vector that delivers instructions to simultaneously kill cancer cells and activate the immune system, with first-in-human trials underway.
Glioblastoma remains one of medicine's most formidable challenges. But as scientists decode the tumor's complex biology — from its hijacked microenvironment to the blood-brain barrier that shields it — each discovery chips away at a disease that has resisted conventional approaches for decades.
